Treatment of infections caused by sensitive strains of anaerobic or aerobic gram-positive microorganisms, including infections accompanied by bacteremia, such as: nosocomial pneumonia; non-hospital pneumonia; complicated infections of the skin and its structures, including infections with diabetic foot without concomitant osteomyelitis, caused by Staphylococcus aureus (methicillin-sensitive and methicillin-resistant isolates), Streptococcus pyogenes or Streptococcus agalactiae; uncomplicated infections of the skin and its structures caused by Staphylococcus aureus (methicillin-sensitive isolates only) or Streptococcus pyogenes; infections caused by enterococci, including vancomycin resistant strains of Enterococcus faecium and faecalis. If the pathogens include gram-negative microorganisms, the purpose of combination therapy is clinically indicated.
Composition and form of release
Zivox is made in solution for infusion, tablets and granules. The active substance of the drug is linezolid.
Zivox is used in the treatment of infectious diseases that are caused by microflora sensitive to linezolid. In the treatment of diseases caused by gram-negative bacteria, the drug is recommended to be used in conjunction with other antibacterial agents.
Zivox is prescribed for:
- community-acquired and nosocomial pneumonia;
- complicated infections of the skin and its appendages;
- skin lesions caused by Streptococcus pyogenes and methicillin-sensitive Staphylococcus aureus;
- infectious diseases caused by enterococci, as well as their strains resistant to vancomycin.
Zivox is not prescribed in case of hypersensitivity to its components, patients under 12 years of age, as well as patients who suffer from uncontrolled hypertension, pheochromocytoma, thyrotoxicosis, carcinoid syndrome.
Zivox should be used with caution in patients who have previously been diagnosed with severe renal insufficiency, pregnancy and lactation, and life-threatening systemic infections.
Use during pregnancy and breastfeeding
The effect of Zivox on fetal development has not been studied at this time. However, animal studies of the drug have revealed embryonic toxicity, which is a serious contraindication for the use of the drug in the treatment of pregnant women. When prescribing Zivox to lactating women, the patient is warned that she should refrain from breastfeeding before starting treatment, as the components of the drug may pass into breast milk.
Method of application and dose
The dose of Zivox is selected individually. When using the drug in solution for infusion, it is administered intravenously. The daily dose is divided into two. Infusion duration from 30 to 120 minutes.
In the treatment of nosocomial and community-acquired pneumonia, as well as infections of the skin and soft tissues, the patient receives 600 mg of the drug every 12 hours. Duration of treatment from 1 to 2 weeks.
When using a suspension prepared from granules or tablets, the drug is taken orally regardless of food.
Granules for the preparation of a suspension for oral administration, coated tablets, a suspension prepared from granules and tablets are taken orally with or without food. In the treatment of hospital and community-acquired forms of pneumonia, the patient receives 600 mg of the drug every 12 hours. In the treatment of skin and soft tissue infections, the patient receives from 400 to 600 mg every 12 hours.
To date, no cases of overdose with Zivox have been reported.
At emergence of signs of poisoning to the patient appoint gastric lavage and reception of activated charcoal
Nausea, diarrhea, abdominal pain, flatulence, constipation, taste changes, cramps, headaches, allergic reactions, vaginal candidiasis, insomnia, fever, headaches and upper respiratory tract infections may occur during treatment with Zivox.
Conditions and terms of storage
Zivox should be stored in a dry place, protected from light and children. The shelf life of the drug is 3 years.